Effect of a Novel Omega-3 and Omega-6 Fatty Acid Supplement on Dry Eye Disease: A 3-month Randomized Controlled Trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

To determine compliance, Omega-3 Index blood tests were conducted.

Who Took Part

Participants with moderate to severe DED were enrolled in a prospective, randomized, double-masked parallel group study.

At baseline and at 1 and 3 months, the following assessments were conducted: Ocular Surface Disease Index (OSDI) questionnaire and Symptom Assessment Questionnaire in Dry Eye, noninvasive tear breakup time, tear meniscus height, tear osmolarity, ocular redness, surface staining, Schirmer test, and meibography.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and parallel-group study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

The Copper (Supplement) group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Dietary Supplements, Docosahexaenoic Acids, Dry Eye Syndromes, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Fatty Acids, Omega-6 and Linoleic Acids.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and parallel-group study of Copper (Supplement).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Optometry and vision science : official publication of the American Academy of Optometry), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.